Artificial Intelligence-guided Precision Treatment of High-grade Serous Ovarian Carcinoma
AI-PTHGSOC
Personalized Precision Diagnosis and Treatment of High-grade Serous Ovarian Carcinoma During the Perioperative Period Assisted by Multi-omics and Artificial Intelligence Models, and Research on the Heterogeneity of Immune Microenvironment
1 other identifier
observational
1,300
0 countries
N/A
Brief Summary
The subjects of this study are patients with high-grade serous ovarian cancer who have undergone surgical resection. The aim is to construct an artificial intelligence model for predicting postoperative recurrence, metastasis and overall survival of patients based on multimodal data such as surgical pathological images (HE images and IHC images of immune microenvironment-related markers), preoperative baseline imaging data and detailed clinical information of patients. In addition, multi-omics sequencing analysis will be used to deeply explore the heterogeneity of the tumor microenvironment, with the expectation of quantifying the postoperative recurrence risk of patients with high-grade serous ovarian cancer and providing new ideas for the precise diagnosis and treatment of patients with high-grade serous ovarian cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2026
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 19, 2026
CompletedFirst Posted
Study publicly available on registry
July 23, 2026
CompletedStudy Start
First participant enrolled
August 1, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 31, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2027
July 23, 2026
July 1, 2026
8 months
July 19, 2026
July 19, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Disease-free survival
through study completion, an average of 1 year
Study Arms (2)
High-Risk Group of Recurrence or Metastasis
AI-assisted patients who have high-risk of postoperative recurrence or metastasis.
Low-Risk Group of Recurrence or Metastasis
AI-assisted patients who have low-risk of postoperative recurrence or metastasis.
Interventions
This study is an retrospective observational study. There will be no interventions on the participants.
Eligibility Criteria
Patients with histologically confirmed high-grade serous ovarian carcinoma (HGSOC)
You may qualify if:
- Histologically confirmed high-grade serous ovarian carcinoma using resection specimens.
- Well-preserved surgical paraffin-embedded tumor specimens.
- Complete clinical information and survival follow-up data.
You may not qualify if:
- Received preoperative neoadjuvant treatment.
- Poor preservation of surgical paraffin specimens.
- Incomplete clinical information and survival follow-up data.
- With concurrent malignancies other than high-grade serous ovarian carcinoma.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- The Affiliated Hospital of Qingdao Universitylead
- Shandong Provincial Hospitalcollaborator
- Yantai Yuhuangding Hospitalcollaborator
- Peking University Third Hospitalcollaborator
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 19, 2026
First Posted
July 23, 2026
Study Start
August 1, 2026
Primary Completion (Estimated)
March 31, 2027
Study Completion (Estimated)
December 31, 2027
Last Updated
July 23, 2026
Record last verified: 2026-07
Data Sharing
- IPD Sharing
- Will not share